Marcos De Lima
Department of Stem Cell Transplantation and Cell Therapy
The University of Texas M. D. Anderson Cancer Center
Houston
Texas 77030
USA
Name/email consistency: high
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. de Lima, M., Giralt, S., Thall, P.F., de Padua Silva, L., Jones, R.B., Komanduri, K., Braun, T.M., Nguyen, H.Q., Champlin, R., Garcia-Manero, G. Cancer (2010)
- Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. de Lima, M., McMannis, J., Gee, A., Komanduri, K., Couriel, D., Andersson, B.S., Hosing, C., Khouri, I., Jones, R., Champlin, R., Karandish, S., Sadeghi, T., Peled, T., Grynspan, F., Daniely, Y., Nagler, A., Shpall, E.J. Bone Marrow Transplant. (2008)
- Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. de Lima, M., Champlin, R.E., Thall, P.F., Wang, X., Martin, T.G., Cook, J.D., McCormick, G., Qazilbash, M., Kebriaei, P., Couriel, D., Shpall, E.J., Khouri, I., Anderlini, P., Hosing, C., Chan, K.W., Andersson, B.S., Patah, P.A., Caldera, Z., Jabbour, E., Giralt, S. Leukemia (2008)
- Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. de Lima, M., Giralt, S. Semin. Hematol. (2006)
- Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. de Lima, M., Couriel, D., Thall, P.F., Wang, X., Madden, T., Jones, R., Shpall, E.J., Shahjahan, M., Pierre, B., Giralt, S., Korbling, M., Russell, J.A., Champlin, R.E., Andersson, B.S. Blood (2004)
- Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. de Lima, M., Anagnostopoulos, A., Munsell, M., Shahjahan, M., Ueno, N., Ippoliti, C., Andersson, B.S., Gajewski, J., Couriel, D., Cortes, J., Donato, M., Neumann, J., Champlin, R., Giralt, S. Blood (2004)
- Ex-vivo purging of hematopoietic progenitor cells. de Lima, M., Shpall, E.J. Curr. Hematol. Rep. (2004)
- Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. de Lima, M., Ravandi, F., Shahjahan, M., Andersson, B., Couriel, D., Donato, M., Khouri, I., Gajewski, J., van Besien, K., Champlin, R., Giralt, S., Kantarjian, H. Cancer (2003)
- Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. De Lima, M., St John, L.S., Wieder, E.D., Lee, M.S., McMannis, J., Karandish, S., Giralt, S., Beran, M., Couriel, D., Korbling, M., Bibawi, S., Champlin, R., Komanduri, K.V. Br. J. Haematol. (2002)
